Evidence map›Paper›PMID 33000534›Full record

ArticleTransfusion medicine (Oxford, England)2021

Emergency response to COVID-19 epidemic: One Chinese blood centre's experience.

Ping Hu, Jianxun Kang, Ying Li, Xiaochun Li, Meng Li, Min Deng, Yuwei Zhao, Hao Tian, Rui Li, Jie Zhang and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Transfusion medicine (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Ping HuCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Jianxun KangCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Ying LiCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Xiaochun LiCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Meng LiCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Min DengCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Yuwei ZhaoCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Hao TianCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Rui LiCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Jie ZhangCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Yan XiCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Wen LiCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Jialiang GaoCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Hua ShanStanford University School of Medicine, Stanford, California, USA.
Xuemei FuCOVID-19 Prevention and Control Working Group, Chengdu Blood Center, Chengdu, Sichuan Province, P.R. China.
Chengdu Center for Disease Control and Prevention · CNSichuan Center for Disease Control and Prevention · CNStanford University · US

Funding

Technology Innovation Research and Development Project of Chengdu Science and Technology Bureau 2020-YF05-00128-SN
6 · The paper itself

Abstract

objectiveThe COVID-19 epidemic has caused a significant global social and economic impact since December 2019. The objective of this study was to demonstrate the emergency response of a Chinese blood centre on maintaining both the safety and the sufficiency of blood supply during large, emerging, infectious epidemics. MATERIALS AND

methodsEarly on in the outbreak of COVID-19, the Chengdu Blood Center developed strategies and implemented a series of measures, including enhanced recruitment efforts, addition of new donation deferral criteria and notification after donation, optimisation of donor experience, development and implementation of a new coronavirus nucleic acid detection technology platform for blood screening and screening all donations for SARS-CoV-2 RNA to maximumly protect the safety of blood supply during a time of unclear risk.

resultsStarting on February 20, the immediate satisfaction rate of blood product orders in Chengdu city's clinical settings reached 100%, and there was no case of blood transfusion infection.

conclusionThe recent experience during the outbreak of SARS-CoV-2 reminded us that improvement in the areas of national and international collaborative programmes for dealing with blood availability and safety concerns during early stages of a disaster and regional and national mechanisms for timely communication with the general public on behalf of blood services should help to better prepare us for future disasters.

Indexed as

SARS-CoV-2AdolescentAdultBlood BanksBlood DonorsBlood SafetyBlood TransfusionChinaCOVID-19COVID-19 SerotherapyDonor SelectionEmergency TreatmentHumansImmunization, PassivePandemicsPlasmablood centerCOVID-19emergency response

Identifiers

PMID33000534
PMCPMC7536997
OpenAlexW3090295039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.